Cancer chemotherapy and biotherapy : principles and practice /

Saved in:
Bibliographic Details
Edition:Fifth edition.
Imprint:Philadelphia : Wolters Kluwer Health/Lippincott Williams & Wilkins, [2011]
©2011
Description:1 online resource (836 pages) : illustrations (some color)
Language:English
Subject:
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/13441441
Hidden Bibliographic Details
Other authors / contributors:Chabner, Bruce.
Longo, Dan L. (Dan Louis), 1949-
ProQuest (Firm)
ISBN:9781605474311
Notes:Includes bibliographical references and index.
Summary:"Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents--their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. The previous edition was one of "Doody's Core Titles 2009." This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised"--Provided by publisher.
Other form:Print version: Cancer chemotherapy and biotherapy : principles and practice. Philadelphia : Wolters Kluwer Health/Lippincott Williams & Wilkins, [2011] xv, 812 pages, 4 unnumbered pages of plates ; 29 cm 9781605474311
Table of Contents:
  • Section 1. Basic Principles Of Cancer Treatment
  • 1. Clinical Strategies for Cancer Treatment: The Role of Drugs
  • 2. Target Identification and Drug Discovery
  • 3. Clinical Drug Development and Approval for Marketing
  • 4. Principles of Pharmacokinetics
  • 5. Special Aspects of Brain Tumor Chemotherapy
  • 6. Pharmacogenetics
  • 7. Barriers to Drug Delivery
  • Section 2. Cytotoxic Agents
  • 8. Antifolates
  • 9. Fluoro-pyrimidines
  • 10. Cytidine Analogues
  • 11. Purine Analogues
  • 12. Hydroxyurea
  • 13. Antimitotic Drugs
  • 14. Alkylating Agents (Including Methylating Agents)
  • 15. Platinum Analogues
  • 16. Antitumor Antibiotics (Including Bleomycin)
  • 17. Topoisomerase I Inhibitors
  • 18. Topoisomerase II Inhibitors: Anthracyclines
  • 19. Topoisomerase II Inhibitors: Etoposide, Teniposide
  • 20. L-Asparaginase
  • Section 3. Molecularly Targeted Therapies
  • 21. Proteosome Inhibitors
  • 22. HDAC Inhibitors
  • 23. Differentiating Agents (Retinoids)
  • 24. Arsenic Trioxide
  • 25. Monoclonal Antibodies: Discovery & Development
  • 26. Anti-angiogenic Agents (Including MonAB)
  • 27. Anti-EGFR Therapies (Including MonAB)
  • 28. Anti-her 2 Therapies
  • 29. Intracellular Signal Inhibitors (bcr-abl)
  • 30. Signal Transduction Inhibitors in Development
  • 31. Inhibitors of the PI3k Pathway & Mitotic Kinase
  • Section 4. Immunologic Agents
  • 32. Interferon and Cytokines
  • 33. Vaccines
  • 34. Adoptive Cellular Therapies
  • 35. Immuno-modulatory Drugs (IMIDS, Anti-CTLA4)
  • Section 5. Hormonal Therapy
  • 36. Hormonal Therapy of Breast Cancer
  • 37. GNRH Agonists and Anti-Androgens
  • Section 6. Supportive Care
  • 38. Pain Management in Cancer Patients
  • 39. Colony Stimulating Factors
  • 40. Anti-nausea Medications
  • 41. Bone Loss Modulators
  • 42. Intravenous Access and Catheter Management
  • Section 7. Survivorship
  • 43. Monitoring for Late Side Effects of Chemotherapy